Searched for
PHARMA STORY SUMMARY
ET Prime Special - Macro the mightiest: Currency movement – it is not just about the US dollar, it is much beyond itThis series is for investors who are keen to understand the nuts and bolts of an economy. How do, for instance, currency rates impact the b...- ETMarkets Smart Talk| Flexicap turnaround: Harish Krishnan explains strategy to navigate cyclical sectorsHarish Krishnan of Aditya Birla Sun Life AMC shares market insights. He reveals the strategy behind flexicap fund success. Krishnan focuses...
- Pharma OTT release announced: When and where to watch Nivin Pauly and Rajit Kapur's Malayalam seriesNivin Pauly makes his web series debut with Pharma, directed by PR Arun. Releasing on JioHotstar in September 2025, the show follows him as...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- F&O Radar| Nifty futures rollover climbs to 79.53%, signals trader confidence ahead: Sudeep ShahThe squeeze sets the stage—the breakout steals the show. For 31 trading sessions, the Nifty moved in a narrow consolidation range, building...
- Reliance 47th AGM 2024: Here is the full speech by Mukesh Ambani, Akash Ambani, Isha Ambani and otherReliance Industries' 47th AGM revealed major updates including bonus shares and the expansion of Jio and Reliance Retail. Chairman Mukesh A...
- Govt should encourage MSME-focused procurement: GAME’s Ravi VenkatesanAddressing access to finance and mitigating delayed payments hold the key to MSMEs’ growth in the country, says Ravi Venkatesan, GAME’s fou...
- Outlook 2024: Who expects what from Dalal Street in the New Year?Entering into the New Year, the outlook for equities remains positive after a splendid 2023 that saw foreign capital and domestic inflows g...
- I would not put my money on the index, the answer lies elsewhere: N Jayakumar, Prime SecuritiesAfter five years of the NDA-1, we see that Nifty has simply mapped global markets, says Jayakumar.
- India, China doing better than EM peers: Adrian Mowat“Emerging Markets down 8% year to date and EM ETFs continue to decline.”
- Clinical trials by pharmaceutical companies still gasping for transparencyData available in the public domain shows Malpani Hospital has conducted over 40 clinical trials for osteoarthritis and rheumatoid arthriti...
- Why Yogesh Mehta is gung-ho on these two spaces“Among NBFCs, we are driving ideas where the prices have corrected or have not changed at all”
- Unlike 2007, earnings have not kept pace in 2017: Mahesh Patil, Birla Sun Life MFNifty PE multiple at about 24 times on a trailing basis, is at the 2007 peak level after which markets crashed
- The jewel of the Indian pharma crown has lost its shine: Amit Ranjan on Sun PharmaSun Pharma got two inspections – one for Mohali and one for Halol sight – and if you summarise, I am sorry to say that the jewel of the Ind...
- TRACK SENSEX, NIFTY LIVE: Who moved my market todayIn this space, ETMarkets.com tracks not just the elite 30 from the Sensex pack, but also showcases the newsmakers and top market movers.
- Don’t see global GDP climbing back to 3.5-4% growth anytime soon: Vallabh Bhanshali, Enam SecuritiesIn an interview with ET Now, Vallabh Bhanshali, Chairman, Enam Securities, shares his views on the market, economic growth and global stabi...
- India's long-term story intact; FIIs governing market buoyancy: Tarun Kataria, Religare Capital Markets"It is still a flowing market and I am not fundamentally bearish because most of the negatives have already factored-in," Tarun Kataria sai...
- Expect markets to surpass lifetime highs: Atul Suri, Trader"The way crude, gold cracked was a very bullish sign. Now as we stand at 6k, but on the flipside we have a very strong global mkt," Suri sa...
- Extremely bearish on crude from long term perspective: says Sandeep Tandon, Quant Capital"India has a potential to give you may be 20-25% returns so we like US a lot so number one pick is US," says Sandeep Tandon.
Load More
